What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
Glaukos secures a permanent J-code for Epioxa. Read why this reimbursement milestone could shape keratoconus treatment adoption and payer access.
Can TECNIS PureSee help Johnson & Johnson win the next phase of premium cataract surgery?
Johnson & Johnson’s TECNIS PureSee data could reshape premium cataract surgery. Read what the ASCRS 2026 findings may change next.
Is Glaukos building a multi-franchise ophthalmology platform through Epioxa and glaucoma implants?
Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.
Why Bausch + Lomb’s ASCRS 2026 data slate matters for premium IOL competition and dry eye care
Find out why Bausch + Lomb’s ASCRS 2026 data package could reshape competition in cataract surgery, dry eye care, and ophthalmology platforms.
Is Alcon redefining the enhanced monofocal category with Clareon TruPlus at ASCRS 2026?
Alcon launched Clareon TruPlus at ASCRS 2026. Read why the new enhanced monofocal IOL could reshape cataract lens choice.
Lupin closes VISUfarma deal, but can branded ophthalmology drive the next phase of growth?
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.
Can Tenpoint Therapeutics’ direct-to-patient YUVEZZI program unlock wider access in the presbyopia market?
Tenpoint Therapeutics and PHIL launch YUVEZZI direct-to-patient access for presbyopia. Read what it means for affordability, uptake, and market adoption.
What Ocugen, Inc.’s OCU410ST milestone means for the race to treat inherited retinal blindness
Discover what Ocugen, Inc.’s OCU410ST milestone means for the future of inherited retinal blindness treatment and the race toward first approval.
Can smaller eyedrops improve glaucoma outcomes? Nanodropper data make the case
Nanodropper’s glaucoma study suggests microdrops may improve pressure control and reduce waste. Read what this could mean for eye care.
Can VeonGen Therapeutics validate VR-based endpoints as Stargardt trials move toward pivotal design
VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.